CapVest Partners-backed Curium has agreed to buy rival US-based radiopharmaceutical company Lantheus in an all-cash deal worth up to nearly $8bn.
The deal will take the Nasdaq-listed Lantheus private.
Under the agreement, Curium US will purchase all outstanding shares of Lantheus for $102.50 per share upon closing.
Lantheus' shareholders are also set to receive non-transferable contingent value rights (CVRs) that could provide up to an additional $12.00 per share if certain commercial milestones for the company's product portfolio are met by 2030. This brings the potential total consideration per share to $114.50.
The offer represents a 38% premium to Lantheus' 60-day volume-weighted average price, a 29% premium to its 30-day average. It is also 21% above the company's closing price as of 21 May 2026, the last day before media reports emerged about the potential sale.
#deal
The deal will take the Nasdaq-listed Lantheus private.
Under the agreement, Curium US will purchase all outstanding shares of Lantheus for $102.50 per share upon closing.
Lantheus' shareholders are also set to receive non-transferable contingent value rights (CVRs) that could provide up to an additional $12.00 per share if certain commercial milestones for the company's product portfolio are met by 2030. This brings the potential total consideration per share to $114.50.
The offer represents a 38% premium to Lantheus' 60-day volume-weighted average price, a 29% premium to its 30-day average. It is also 21% above the company's closing price as of 21 May 2026, the last day before media reports emerged about the potential sale.
#deal
2 months ago
